Dengvaxia (Sanofi) is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. It is designed to protect against all four DENV serotypes. It was licensed by the FDA in May 2019 for children and adolescents age 9 through 16 years with a confirmed history of previous dengue infection. FDA lowered the youngest age for licensed use from 9 years to 6 years in 2023; however, CDC’s recommendations to begin routine vaccination of children with serologic evidence of prior dengue infection at age 9 years remains unchanged. The recommendation for vaccination is restricted to people age 9 through 16 years with confirmed previous DENV infection because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination.

In 2024, Sanofi announced plans to discontinue production of Dengvaxia in the third quarter of 2026 due to low global demand. Other dengue vaccines are in late stages of development; however, there are no other licensed dengue vaccines available in the United States.